Arizona State Retirement System acquired a new stake in shares of Bioventus Inc. (NYSE:BVS – Free Report) in the fourth quarter, HoldingsChannel reports. The fund acquired 10,396 shares of the company’s stock, valued at approximately $109,000.
A number of other institutional investors have also recently bought and sold shares of BVS. Royce & Associates LP acquired a new stake in Bioventus during the third quarter valued at $8,337,000. Segall Bryant & Hamill LLC acquired a new stake in shares of Bioventus in the third quarter worth about $4,515,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Bioventus in the third quarter worth about $3,092,000. State Street Corp lifted its position in shares of Bioventus by 38.8% in the third quarter. State Street Corp now owns 676,501 shares of the company’s stock worth $8,084,000 after buying an additional 189,216 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of Bioventus by 228.3% in the third quarter. JPMorgan Chase & Co. now owns 253,740 shares of the company’s stock worth $3,032,000 after buying an additional 176,442 shares during the last quarter. Institutional investors and hedge funds own 62.94% of the company’s stock.
Insider Buying and Selling
In related news, SVP Anthony D’adamio sold 4,380 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total transaction of $44,632.20. Following the transaction, the senior vice president now directly owns 118,178 shares in the company, valued at $1,204,233.82. The trade was a 3.57 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Katrina J. Church sold 2,535 shares of the business’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $10.53, for a total value of $26,693.55. Following the transaction, the senior vice president now owns 47,264 shares in the company, valued at $497,689.92. This represents a 5.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 52,932 shares of company stock valued at $512,511. Insiders own 32.90% of the company’s stock.
Bioventus Price Performance
Analyst Ratings Changes
Separately, JPMorgan Chase & Co. raised Bioventus from an “underweight” rating to a “neutral” rating and boosted their price target for the stock from $12.00 to $13.00 in a research report on Tuesday, December 17th.
Check Out Our Latest Analysis on BVS
Bioventus Profile
Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.
Recommended Stories
- Five stocks we like better than Bioventus
- What Makes a Stock a Good Dividend Stock?
- How to Build the Ultimate Everything ETF Portfolio
- What Are the FAANG Stocks and Are They Good Investments?
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Business Services Stocks Investing
- 3 Stocks With High ROE and Market-Beating Growth Potential
Want to see what other hedge funds are holding BVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioventus Inc. (NYSE:BVS – Free Report).
Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.